Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenetics and bipolar disorder.

F Mamdani1, I Jaitovich Groisman, M Alda

  • 1Douglas Hospital Research Centre, McGill University, Montreal, Quebec, Canada.

The Pharmacogenomics Journal
|April 14, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lithium response in families can inform the selection of long-term treatment of bipolar disorder.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same author

Family History and Solar Insolation in Bipolar I Disorder.

Acta psychiatrica Scandinavica·2026
Same author

Sampling of natural speech for the assessment of psychopathology: data collection procedure and inter-rater reliability.

Psychiatry research·2025
Same author

Altered tRNA expression profile associated with codon-specific proteomic changes in the suicide brain.

Molecular psychiatry·2025
Same author

Associations between epigenetic aging and childhood peer victimization, depression, and suicidal ideation in adolescence and adulthood: A study of two population-based samples.

Frontiers in cell and developmental biology·2023
Same author

Association between childhood cognitive skills & adult suicidal behavior: A systematic review and meta-analysis.

Journal of affective disorders·2023
Same journal

Toxicity related to immunotherapy in urothelial cancer: Tumour genetic risk variants.

The pharmacogenomics journal·2026
Same journal

Beyond the 'Pregnancy Black Box': a global roadmap for artificial intelligence-driven pharmacogenomics in maternal-neonatal health.

The pharmacogenomics journal·2026
Same journal

The association of ABCB1, CYP2C19 and CYP2C9 combined activity with clopidogrel resistance in patients with recurrent ischemic stroke.

The pharmacogenomics journal·2026
Same journal

Development and validation of an open data model for pharmacogenetics to enable semantic interoperability in clinical practice.

The pharmacogenomics journal·2026
Same journal

Finasteride, pharmacogenomics, and suicide risk: a public health concern.

The pharmacogenomics journal·2026
Same journal

Cost-effectiveness of genome-guided statin treatment for hypercholesterolemia.

The pharmacogenomics journal·2026
See all related articles

Pharmacogenetics offers personalized treatment for bipolar disorder (BD), but current studies require validation. Standardizing drug response criteria is crucial for advancing personalized medicine in BD treatment.

Area of Science:

  • Psychiatry
  • Genetics
  • Pharmacology

Background:

  • Bipolar disorder (BD) necessitates varied treatments with significant individual response differences.
  • Pharmacogenetics presents opportunities for personalized therapeutic strategies in BD.
  • Existing treatments for BD exhibit considerable variability in efficacy and side effects.

Purpose of the Study:

  • To review pharmacogenetic strategies applied to bipolar disorder treatment.
  • To assess the current state and challenges of pharmacogenetics in BD research.
  • To highlight the need for standardized response criteria in pharmacogenetic studies for BD.

Main Methods:

  • Non-systematic review of studies utilizing pharmacogenetic strategies in BD.
  • Analysis of studies focusing on lithium response and antidepressant treatment response.

Related Experiment Videos

  • Examination of genetic factors influencing treatment outcomes in BD.

    • Main Results:

    • Most pharmacogenetic studies in BD have focused on lithium response.
    • Emerging research investigates genetic factors in mixed samples based on antidepressant response.
    • Current molecular studies are preliminary and require external validation.

    Conclusions:

    • Pharmacogenetic strategies show promise for improving BD treatment homogeneity and identifying genetic mediators of response.
    • Comparability issues between studies stem from differing response definition criteria.
    • Standardization of drug response criteria is essential for advancing pharmacogenetic research in bipolar disorder.